{
    "id": 2157,
    "fullName": "PTEN inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "PTEN inact mut indicates that this variant results in a loss of function of the Pten protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 5728,
        "geneSymbol": "PTEN",
        "terms": [
            "PTEN",
            "10q23del",
            "BZS",
            "CWS1",
            "DEC",
            "GLM2",
            "MHAM",
            "MMAC1",
            "PTEN1",
            "PTENbeta",
            "TEP1"
        ]
    },
    "variant": "inact mut",
    "createDate": "10/09/2014",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8366,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a PTEN deficient estrogen-receptor (ER) positive breast cancer cell line demonstrated increased sensitivity to treatment in culture when Pictilisib (GDC-0941) was given at a higher dose for a shorter duration, resulting in inhibition of cell growth (PMID: 26733612).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6631,
                    "pubMedId": 26733612,
                    "title": "Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26733612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10704,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 1051,
                "therapyName": "SAR245409",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8941,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3023414 inhibited proliferation of renal cancer cells harboring PTEN inactivating mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 1069,
                "therapyName": "LY3023414",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6792,
                    "pubMedId": 27439478,
                    "title": "Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10709,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation (PMID: 24634413) was sensitive to SF1126, demonstrating inhibition of tumor growth in cell line xenograft models (PMID: 18172313).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 915,
                "therapyName": "SF1126",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                },
                {
                    "id": 8775,
                    "pubMedId": 18172313,
                    "title": "A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18172313"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6322,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL147 inhibited PI3K signaling, growth, and migration of a human prostate adenocarcinoma cell line harboring a PTEN inactivating mutation in culture, and inhibited tumor growth and vascularization in xenograft models (PMID: 25637314).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 2526,
                "name": "prostate adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8367,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Faslodex (fulvestrant) and PIctilisib (GDC-0941) resulted in decreased cell viability and increased apoptotic activity in PTEN deficient estrogen-receptor (ER) positive breast cancer cells in culture (PMID: 26733612).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 4357,
                "therapyName": "Fulvestrant + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6631,
                    "pubMedId": 26733612,
                    "title": "Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26733612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6338,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of XL147 and Taxol (paclitaxel) inhibited tumor growth and angiogenesis in xenograft models of a human prostate adenocarcinoma cell line harboring an inactivating mutation in PTEN, with increased efficacy compared to either agent alone (PMID: 25637314).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 4115,
                "therapyName": "Paclitaxel + XL147",
                "synonyms": null
            },
            "indication": {
                "id": 2526,
                "name": "prostate adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9814,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with inactivating Pten mutations (PMID: 22294718).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 693,
                    "pubMedId": 22294718,
                    "title": "Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22294718"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20740,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, inactivating PTEN mutations were identified in 3 of 100 patients with non-small cell lung cancer at treatment discontinuation of Tagrisso (osimertinib) (PMID: 31839416).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18023,
                    "pubMedId": 31839416,
                    "title": "Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31839416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6133,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4065,
                "therapyName": "Alpelisib + Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6110,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4048,
                "therapyName": "AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6117,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4054,
                "therapyName": "AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6128,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4060,
                "therapyName": "AZD6482 + Binimetinib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6106,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4047,
                "therapyName": "Alpelisib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6099,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6100,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6126,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4061,
                "therapyName": "AZD6482 + Encorafenib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6137,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4068,
                "therapyName": "Encorafenib + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6136,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4067,
                "therapyName": "GSK2636771 + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6113,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4049,
                "therapyName": "Alpelisib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6111,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4055,
                "therapyName": "Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6098,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 2514,
                "therapyName": "TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6130,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4064,
                "therapyName": "AZD6482 + Binimetinib + Encorafenib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6101,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 3714,
                "therapyName": "Alpelisib + AZD6482",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6105,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4046,
                "therapyName": "NVP-AEW541 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6115,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4053,
                "therapyName": "Binimetinib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6131,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4063,
                "therapyName": "Alpelisib + AZD6482 + Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6119,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 1311,
                "therapyName": "Alpelisib + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6102,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4042,
                "therapyName": "Alpelisib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6109,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4056,
                "therapyName": "Encorafenib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6125,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4062,
                "therapyName": "Alpelisib + AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6103,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4044,
                "therapyName": "AZD6482 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6127,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4059,
                "therapyName": "Alpelisib + AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6104,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4045,
                "therapyName": "GSK2636771 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6097,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 659,
                "therapyName": "AZD6482",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6138,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4069,
                "therapyName": "Encorafenib + GSK2636771 + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6118,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4052,
                "therapyName": "Binimetinib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7389,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the AZD5363 inhibited proliferation of several endocrine-sensitive and resistant estrogen receptor (ESR1)-positive breast cancer cell lines in culture, including a cell line with PTEN inactivation (PMID: 26116361).",
            "molecularProfile": {
                "id": 25362,
                "profileName": "ESR1 pos PTEN inact mut"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6340,
                    "pubMedId": 26116361,
                    "title": "AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9189,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",
            "molecularProfile": {
                "id": 26770,
                "profileName": "APC inact mut PTEN inact mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9199,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",
            "molecularProfile": {
                "id": 26770,
                "profileName": "APC inact mut PTEN inact mut"
            },
            "therapy": {
                "id": 4932,
                "therapyName": "BEZ235 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9192,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",
            "molecularProfile": {
                "id": 26770,
                "profileName": "APC inact mut PTEN inact mut"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9194,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9201,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 4932,
                "therapyName": "BEZ235 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2095,
            "profileName": "PTEN inact mut",
            "profileTreatmentApproaches": [
                {
                    "id": 2323,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PTEN inact mut"
                },
                {
                    "id": 2322,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PTEN inact mut"
                },
                {
                    "id": 2309,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PTEN inact mut"
                },
                {
                    "id": 12417,
                    "name": "PIK3CB inhibitor",
                    "profileName": "PTEN inact mut"
                },
                {
                    "id": 2308,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PTEN inact mut"
                }
            ]
        },
        {
            "id": 22705,
            "profileName": "BRAF mut PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25362,
            "profileName": "ESR1 pos PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26218,
            "profileName": "PIK3CA wild-type PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26219,
            "profileName": "PIK3CA D1029Y PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26770,
            "profileName": "APC inact mut PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26772,
            "profileName": "APC inact mut KRAS G12D PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}